FilingsTodayHyundai Bioland
At a glance
Hyundai Bioland filed 30 disclosures in the last 12 months, including 3 earnings. The most recent key filing was on Aug 3.
Revenue for 2025 was ₩131B, up 9.2% on 2024. Operating margin was 9.7% against 13.7% a year earlier. Debt was 23% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩78.5B and operating profit of ₩12.2B.
The 2025 annual report lists 342 employees with an average tenure of 8.8 years and average pay of ₩66.9M, #695 of 1,829 listed companies by average pay. Its 9 directors and auditors were paid ₩136.4M each on average. It paid ₩70 per common share in cash dividends, against ₩70 a year earlier (+0%). (주)현대퓨처넷 and related parties held 35.00% at year end.
From the 2025 annual report
Staff: 342 (250 men, 92 women), of whom 9 on fixed-term contracts. Total pay for the year: ₩22.9B. Directors and auditors: 9, paid ₩1.2B in total.
Dividends (common shares)
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash dividend per share | ₩70 | ₩70 | ₩70 |
| Payout ratio | 831.2% | 36.8% | 13% |
| Yield (as filed) | 1.60% | 1.70% | 0.70% |
| Total cash dividends | ₩2.1B | ₩2.1B | ₩1.1B |
Largest shareholder
(주)현대퓨처넷 holds 35.00%; with 0 related parties the group holds 35.00% of common shares at year end.
Individuals paid ₩500M or more
| 이희준 대표이사 | ₩736.9M |
Auditor: 한영회계법인 · opinion: Unqualified.
Source: 2025 annual business report (DART). How figures are combined
Financial summary
Key filings
Other filings
Links open the original filing on DART, in Korean.